Discovery of Novel CYP17 Inhibitors for the Treatment of Prostate Cancer with Structure-Based Drug Design

Author(s): Pelin Armutlu, Muhuttin Emre Ozdemir, Sule Ozdas, Ibrahim Halil Kavakli, Metin Turkay

Journal Name: Letters in Drug Design & Discovery

Volume 6 , Issue 5 , 2009

Become EABM
Become Reviewer


It has been shown that prostate cancer is associated with elevated androgen biosynthesis; therefore, inhibiting the activity of Cytochrome P450 17 (CYP17) may prevent progression of prostate cancer. In this study we identified, using in silico and experimental methods, two novel steroidal and non-steroidal lead compounds that inhibit the activity CYP17.

Keywords: Prostate Cancer, Androgen Biosynthesis, Cytochrome P450 enzyme 17R-hydroxylase-17, 20-lyase, Virtual Screening

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [337 - 344]
Pages: 8
DOI: 10.2174/1570180810906050337
Price: $65

Article Metrics

PDF: 8